文献速递类风湿关节炎

类风湿关节炎患者托法替布与静脉血栓栓塞风险:基于人群的队列研究

Risk of venous thromboembolism associated with tofacitinib in patients with rheumatoid arthritis: a population-based cohort study.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

经倾向评分加权和Meta分析合并后,托法替布与TNF抑制剂相比VTE风险无显著差异(合并HR 1.13,95%CI 0.77-1.65)。总体VTE发生率低于每100人年1例。

要点

  • 在三个数据库中,托法替布与TNF抑制剂的VTE风险均无显著差异。
  • 合并HR为1.13(95%CI 0.77-1.65),提示无证据支持托法替布增加VTE风险。
  • 总人群VTE发生率低于1/100人年。

核心结论

  • 在类风湿关节炎患者中,托法替布与TNF抑制剂相比未观察到静脉血栓栓塞风险增加。

研究设计与样本

  • 基于IBM MarketScan(2012-18)、Medicare(2012-17)和Optum Clinformatics(2012-19)三个数据库的回顾性队列研究。
  • 纳入未使用过生物制剂或托法替布的类风湿关节炎患者,随访至停药、换药、脱保或行政删失。
  • 采用倾向评分精细分层加权控制混杂,Cox比例风险模型估计HR,逆方差Meta分析合并各数据库结果。

主要发现

  • 托法替布和TNF抑制剂的粗发生率(每100人年)分别为:MarketScan 0.42(95%CI 0.20-0.77)和0.35(0.29-0.42);Medicare 1.18(0.68-1.92)和0.83(0.71-0.97);Optum 0.19(0.04-0.57)和0.34(0.26-0.44)。
  • 各数据库倾向评分加权HR均无显著差异,合并HR为1.13(95%CI 0.77-1.65)。

关键数值与推荐

  • 主要结局VTE通过住院索赔中的肺栓塞或深静脉血栓诊断识别。
  • 合并HR 1.13(95%CI 0.77-1.65)无统计学显著性。

临床怎么用

  • 在类风湿关节炎患者中,托法替布与TNF抑制剂的VTE风险总体相似,临床决策时可结合患者个体血栓风险综合评估。

局限性

  • 原文未报告局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the risk of venous thromboembolism (VTE) with tofacitinib compared with TNFis in patients with RA. METHODS: RA patients initiating tofacitinib or a TNFi without use of any biologic or tofacitinib any time prior were identified from IBM 'MarketScan' (2012-18), Medicare (parts A, B and D, 2012-17) or 'Optum' Clinformatics (2012-19) and followed until treatment discontinuation, treatment switch, insurance disenrollment or administrative censoring. The primary outcome, VTE, was identified using inpatient claims for pulmonary embolism or deep vein thrombosis. A Cox proportional hazards model provided hazard ratio (HR) and 95% CIs after accounting for confounding through propensity score fine-stratification weighting. HRs were pooled across databases with inverse variance meta-analytic method. RESULTS: A total of 42 201, 25 078 and 20 374 RA patients were identified from MarketScan, Medicare and Optum, respectively, of whom 7.1, 7.1 and 9.7% were tofacitinib initiators. The crude incidence rates per 100 person-years (95% CI) were 0.42 (0.20-0.77) and 0.35 (0.29-0.42) in MarketScan, 1.18 (0.68-1.92) and 0.83 (0.71-0.97) in Medicare, and 0.19 (0.04-0.57) and 0.34 (0.26-0.44) in Optum for tofacitinib and TNFis, respectively. Propensity score-weighted HRs showed no significant differences in the risk of VTE between tofacitinib and TNFis in any database with a pooled HR (95% CI) of 1.13 (0.77-1.65). CONCLUSION: Overall, VTE occurred infrequently (<1 per 100) in a total of 87 653 RA patients initiating tofacitinib or a TNFi. We observed no evidence for an increased risk of VTE for tofacitinib vs TNFis in RA patients.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Desai RJ, Pawar A, Khosrow-Khavar F, et al. Risk of venous thromboembolism associated with tofacitinib in patients with rheumatoid arthritis: a population-based cohort study. Rheumatology (Oxford). 2021. PMID: 33752237. doi:10.1093/rheumatology/keab294

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。